Pharma Doesn’t Buy on Features. They Buy on Fear of LOE: Sell more drugs by knowing when they die
The pharmaceutical industry faces a financial contraction of historic proportions. Between 2025 and 2030, $300 billion in annual prescription drug […]
The pharmaceutical industry faces a financial contraction of historic proportions. Between 2025 and 2030, $300 billion in annual prescription drug […]
The $400 Billion Revenue Precipice The biopharmaceutical sector is entering a period of revenue contraction that threatens the financial stability
From Pill to Platform: The Pre-LOE Device Playbook. Read Post »
The global pharmaceutical industry is currently navigating a pivotal transition characterized by a monumental wave of patent expirations that will
The contemporary pharmaceutical landscape is defined by a paradigm shift in lifecycle management (LCM), moving beyond traditional defensive tactics toward
How Formulation Vendors Can Turn Loss of Exclusivity Into a 24-Month Sales Window Read Post »
The global biopharmaceutical industry is undergoing a structural transformation characterized by the convergence of advanced material science, stringent regulatory evolution,
How Smart Biopharma Packaging Teams Turn Label Changes Into Market Share Read Post »
Between 2025 and 2030, the pharmaceutical industry faces a revenue collapse of $200 billion to $400 billion as nearly 200
How Pharmaceutical Packaging Companies can Win the Patent Cliff Read Post »
The metabolic health market is currently witnessing a capital migration of historic proportions. If we look at the numbers, the
How to bypass the GLP-1 patent lock Read Post »
The Economic Reality of the Patent Cliff The pharmaceutical industry is currently facing a structural shift in how it calculates
CDMO Patent Cliff Battle Plan: Cut Costs, Keep Clients Read Post »
The global pharmaceutical sector is currently confronting a revenue transition of unprecedented scale, characterized by the convergence of the most
Get fresh news and insights, drug patent expirations & more…